Pharmafile Logo
Pharmafocus logo
Advanced Search

non-small cell lung cancer

Showing 15 posts of 40 posts found.

HUTCHMED completes enrolment in phase 3 trial for lung cancer

August 21, 2025
Research and Development HUTCHMED, Oncology, clinical trial, lung cancer, non-small cell lung cancer

HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use of ORPATHYS (savolitinib) in combination …

News

FDA grants accelerated approval for advanced non-small cell lung cancer treatment

July 4, 2025
Medical Communications, Research and Development Breakthrough Therapy Designation, Oncology, US Food and Drug Administration, Zegfrovy, clinical trial, non-small cell lung cancer, priority review

The US Food and Drug Administration (FDA) has granted accelerated approval to Dizal Therapeutic’s Zegfrovy (sunvozertinib) for the treatment of …

News

Combination first-in-line treatment approved for patients with non-small cell lung cancer

January 23, 2025
Research and Development J&J Innovative Medicine, Oncology, approval, non-small cell lung cancer

Johnson & Johnson Innovative Medicine  have announced that the European Commission (EC) has approved a marketing authorisation for the combination …

News

NDA in China receives priority review status for lung cancer treatment

January 3, 2025
Research and Development China, China National Medical products Administration, HUTCHMED, NDA, Oncology, epidermal growth factor receptor, non-small cell lung cancer, priority review

HUTCHMED have announced that the China National Medical Products Administration (NMPA) have granted a priority review for a new drug …

News
lungs

European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients

August 27, 2024
Research and Development J&J, Oncology, chemotherapy, non-small cell lung cancer

Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission (EC) has approved a combined …

News

Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI  in combination with MEKTOVI  for the treatment of adult patients with advanced non-small cell lung cancer  NSCLC) with a BRAFV600E mutation

July 29, 2024
Clinical Trial Services BRAF mutation, CHMP, EMA, Oncology, Pierre Fabre Laboratories, colorectal cancer, european studies, non-small cell lung cancer

Pierre Fabre Laboratories has announced a positive opinion from the European Medical Association’s (EMA) Committee for Medicinal Products Human use …

News
merckwindow_web

FDA expands Keytruda label to include stage 3 and 4 non-small cell lung cancer

April 12, 2019
Medical Communications, Research and Development Cancer, MSD, keytruda, lung cancer, non-small cell lung cancer, pharma

MSD has revealed that its anti-PD-1 therapy Keytruda (pembrolizumab) has received expanded indication from the FDA to include the first-line …

News

European approval for Pfizer’s Vizimpro in first-line non-small cell lung cancer

April 4, 2019
Sales and Marketing Cancer, Europe, Pfizer, Vizimpro, lung cancer, non small cell lung cancer, non-small cell lung cancer, pharma

The European Commission has awarded marketing approval to Pfizer’s tyrosine kinase inhibitor (TKI) Vizimpro (dacomitinib), it has emerged, as a …

News

AZ to rework ongoing immuno-oncology trials to “enhance options”

January 17, 2017
Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, non-small cell lung cancer

Due to the “strong efficacy” shown by its durvalumab as a treatment for non-small cell lung cancer (NSCLC), AstraZeneca has …

News
shutterstock_232245868

Personalised medicine to drive global lung cancer market to 2020

November 29, 2016
Manufacturing and Production, Sales and Marketing Technavio, lung cancer, non-small cell lung cancer

According to a new report from Technavio, the global lung cancer therapeutics market is projected to grow at more than …

News
shutterstock_231613360

Non-small cell lung cancer market to hit $26bn by 2025

November 24, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GlobalData, non-small cell lung cancer

New research from GlobalData has indicated that the non-small cell lung cancer (NSCLC) market will rise in value by over …

News
merck_and_co

FDA to review MSD’s Keytruda as a first-line lung cancer treatment

September 7, 2016
Research and Development FDA, MSD, Merck, first-line, keytruda, lung cancer, non-small cell lung cancer, opdivo

The US Food and Drug Administration has accepted the supplemental biologics license application from MSD, known as Merck in the …

News
pfizer_chrome_plate

Pfizer nabs EU approval for Xalkori for certain lung cancers

August 31, 2016
Sales and Marketing Pfizer, Xalkori, lung cancer, non-small cell lung cancer

The European Commission has approved Pfizer’s Xalkori (crizotinib) for the treatment of adults with ROS1-positive advanced non-small cell lung cancer …

News
astrazeneca_building_white

AstraZeneca’s selumetinib fails to meet primary endpoint in lung cancer trial again

August 9, 2016
Manufacturing and Production AstraZeneca, failure, non-small cell lung cancer, phase III, selumetinib, trial failure

AstraZeneca has announced that its MEK 1/2 inhibitor, selumetinib, failed to meet its primary endpoint of progression free survival in …

News
AZ sign

AstraZeneca’s Tagrisso gets EU lung cancer sign-off

February 4, 2016
Sales and Marketing AstraZeneca, European Commission, NSCLC, Tagrisso, non-small cell lung cancer, osimertinib

The European Commission (EC) has granted conditional marketing authorisation to AstraZeneca’s Tagrisso to treat locally advanced or metastatic non-small cell …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026